US Patent Application 18248757. METHODS TO PREDICT OUTCOMES TO CHIMERIC ANTIGEN RECEPTOR T-CELLS IN LYMPHOMA FROM CELL-FREE DNA AND GENETIC MUTATIONS simplified abstract

METHODS TO PREDICT OUTCOMES TO CHIMERIC ANTIGEN RECEPTOR T-CELLS IN LYMPHOMA FROM CELL-FREE DNA AND GENETIC MUTATIONS

Organization Name

The Board of Trustees of the Leland Stanford Junior University

Inventor(s)

David M. Kurtz of Stanford CA (US)

Brian Sworder of Stanford CA (US)

Arash Ash Alizadeh of Stanford CA (US)

Maximilian Diehn of Stanford CA (US)

Matthew Frank of Stanford CA (US)

David B. Miklos of Stanford CA (US)

Crystal Mackall of Stanford CA (US)

METHODS TO PREDICT OUTCOMES TO CHIMERIC ANTIGEN RECEPTOR T-CELLS IN LYMPHOMA FROM CELL-FREE DNA AND GENETIC MUTATIONS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18248757 titled 'METHODS TO PREDICT OUTCOMES TO CHIMERIC ANTIGEN RECEPTOR T-CELLS IN LYMPHOMA FROM CELL-FREE DNA AND GENETIC MUTATIONS

Simplified Explanation

- This patent application is about using cell-free DNA from a liquid biopsy to track DNA from both tumors and CAR T-cells in individuals. - The application also describes methods for predicting how individuals will respond to therapy, specifically CAR T-cell therapies. - The patent application also covers methods for treating individuals with cancer, particularly lymphoma.

Original Abstract Submitted

The present disclosure generally relates to methods that utilize cell-free DNA from a liquid biopsy of an individual to track DNA from both the tumor and the chimeric antigen receptor (CAR) T-cells. The present disclosure further relates to methods of predicting individuals' response to therapy, e.g., CAR T-cell therapies. Additionally, the present disclosure relates to methods of treating individuals with cancer, such as lymphoma.